ES2086029T3 - Composiciones farmaceuticas solidas para la administracion oral con permanencia gastrica prolongada. - Google Patents

Composiciones farmaceuticas solidas para la administracion oral con permanencia gastrica prolongada.

Info

Publication number
ES2086029T3
ES2086029T3 ES92113187T ES92113187T ES2086029T3 ES 2086029 T3 ES2086029 T3 ES 2086029T3 ES 92113187 T ES92113187 T ES 92113187T ES 92113187 T ES92113187 T ES 92113187T ES 2086029 T3 ES2086029 T3 ES 2086029T3
Authority
ES
Spain
Prior art keywords
permanence
oral administration
pharmaceutical compositions
solid pharmaceutical
long gastric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92113187T
Other languages
English (en)
Inventor
Pierandrea Esposito
Fabio Carli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vectorpharma International SpA
Original Assignee
Vectorpharma International SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vectorpharma International SpA filed Critical Vectorpharma International SpA
Application granted granted Critical
Publication of ES2086029T3 publication Critical patent/ES2086029T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Abstract

COMPOSICIONES FARMACEUTICAS SOLIDAS DE ADMINISTRACION ORAL, CON UNA PERMANENCIA EN EL ESTOMAGO PROLONGADA, QUE CONSISTEN EN UNA O MAS SUSTANCIAS INORGANICAS DE GRAN DENSIDAD, UNA O MAS SUSTANCIAS BIOADHESIVAS, UN INGREDIENTE ACTIVO, BIEN POR SI SOLO O MEZCLADO EN UN SISTEMA PORTADOR, ASI COMO EXCIPIENTES, LUBRICANTES Y OTROS MATERIALES NORMALMENTE UTILIZADOS EN LAS FORMULACIONES FARMACEUTICAS.
ES92113187T 1991-08-06 1992-08-03 Composiciones farmaceuticas solidas para la administracion oral con permanencia gastrica prolongada. Expired - Lifetime ES2086029T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI912212A IT1251153B (it) 1991-08-06 1991-08-06 Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica

Publications (1)

Publication Number Publication Date
ES2086029T3 true ES2086029T3 (es) 1996-06-16

Family

ID=11360543

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92113187T Expired - Lifetime ES2086029T3 (es) 1991-08-06 1992-08-03 Composiciones farmaceuticas solidas para la administracion oral con permanencia gastrica prolongada.

Country Status (5)

Country Link
EP (1) EP0526862B1 (es)
AT (1) ATE134134T1 (es)
DE (1) DE69208299T2 (es)
ES (1) ES2086029T3 (es)
IT (1) IT1251153B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3332426B2 (ja) * 1992-10-02 2002-10-07 太田製薬株式会社 大腸および小腸の検査用ｘ線造影剤
WO1994020074A1 (en) * 1993-03-12 1994-09-15 The Procter & Gamble Company Adsorbate compositions
FR2703250A1 (fr) * 1993-03-30 1994-10-07 Chicouri Marcel Nouvelles compositions pharmaceutiques à base de bismuth et leur procédé de préparation.
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
IL119660A (en) 1993-05-10 2002-09-12 Euro Celtique Sa Controlled release formulation comprising tramadol
IT1265074B1 (it) * 1993-05-18 1996-10-30 Istituto Biochimico Italiano Composizione farmaceutica a lento rilascio contenente come sostanza attiva un acido biliare
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5891471A (en) 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
KR100354702B1 (ko) 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
DE4404011A1 (de) * 1994-02-09 1995-08-10 Jenapharm Gmbh Neue, adhäsiv wirkende Zubereitungen für mit Flüssigkeit benetzte Oberflächen, Verfahren und Vorrichtung zur Erfassung der Adhäsionszeit diesbezüglicher Zubereitungen
US5843480A (en) 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
CH687810A5 (de) * 1995-05-24 1997-02-28 Mepha Ag Pelletformulierung mit Omeprazol.
WO1996039126A2 (en) * 1995-06-06 1996-12-12 Warner-Lambert Company Ranitidine salts on magnesium trisilicate as an adsorbate
ES2112765B1 (es) * 1995-08-02 1999-03-01 Cantabria Ind Farmaceutica Sa Procedimiento para la obtencion de formulaciones de constraste radiologico, para exploraciones gastrointestinales de uso extemporaneo y directo.
DE19533162A1 (de) * 1995-09-08 1997-03-13 Bayer Ag Pharmazeutisches Kombinationspräparat mit Ketoprofen
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
US6368586B1 (en) 1996-01-26 2002-04-09 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
US5985312A (en) * 1996-01-26 1999-11-16 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
GB9607955D0 (en) * 1996-04-17 1996-06-19 Tillotts Pharma Ag Hydrophobic carbomer salt compositions
AU3481497A (en) * 1996-06-11 1998-01-07 Zonagen, Inc. Chitosan drug delivery system
AU5446798A (en) * 1996-11-27 1998-06-22 Procter & Gamble Company, The Compositions and methods for the treatment of gastrointestinal disorders
GB2329334A (en) * 1997-09-18 1999-03-24 Reckitt & Colmann Prod Ltd Cholesterol-lowering agents
SE9704869D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
WO1999062560A1 (en) * 1998-06-05 1999-12-09 Warner-Lambert Company Stabilization of compositions containing ace inhibitors using magnesium oxide
JP4988088B2 (ja) 1998-08-12 2012-08-01 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリジン−２−イルメチルスルフィニル−１ｈ−ベンズイミダゾール、もしくはピリジン−２−イルメチルスルフィニル−１ｈ−ベンズイミダゾールの骨格を有する化合物、またはその薬学的に許容される塩の経口投与形組成物を固定的に組み合わせた組成物
US6319513B1 (en) 1998-08-24 2001-11-20 The Procter & Gamble Company Oral liquid mucoadhesive compounds
WO2000033818A1 (en) * 1998-12-11 2000-06-15 Nostrum Pharmaceuticals, Inc. Sustained release tablet containing hydrocolloid and cellulose ether
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
EP1231896A4 (en) * 1999-11-16 2003-07-09 Ranbaxy Lab Ltd MASK TASTE ORAL COMPOSITIONS
MXPA02007254A (es) 2000-02-04 2002-12-09 Depomed Inc Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero.
UA82824C2 (uk) * 2000-06-21 2008-05-26 К'Юбіст Фармасьютікалз, Інк. Композиція і спосіб поліпшення перорального всмоктування протимікробних засобів
US6248360B1 (en) 2000-06-21 2001-06-19 International Health Management Associates, Inc. Complexes to improve oral absorption of poorly absorbable antibiotics
US7527807B2 (en) 2000-06-21 2009-05-05 Cubist Pharmaceuticals, Inc. Compositions and methods for increasing the oral absorption of antimicrobials
GB2373438A (en) * 2001-02-10 2002-09-25 Reckitt & Colmann Prod Ltd Cholesterol lowering compositions
IL157634A0 (en) * 2001-03-13 2004-03-28 Penwest Pharmaceuticals Co Chronotherapeutic dosage forms containing glucocorticosteroid
US20030158254A1 (en) * 2002-01-24 2003-08-21 Xenoport, Inc. Engineering absorption of therapeutic compounds via colonic transporters
MXPA06003101A (es) 2003-09-19 2006-06-20 Penwest Pharmaceuticals Co Formas de dosis cronoterapeuticas.
BRPI0414311A (pt) 2003-09-19 2008-03-04 Penwest Pharmaceutical Co formas de dosagem de liberação controlada
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
DE102004023069A1 (de) 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
CA2606386C (en) 2005-04-29 2014-06-10 Cubist Pharmaceuticals, Inc. Therapeutic compositions
CN101516353B (zh) * 2006-08-30 2013-10-16 雅戈泰克股份公司 包含核心和一个或多个阻挡层的控释口服制剂
AU2013202344B2 (en) * 2006-08-30 2014-07-17 Jagotec Ag Controlled release oral dosage formulations comprising a core and one or more barrier layers
US9101544B2 (en) 2006-08-30 2015-08-11 Jagotec Ag Controlled release nisoldipine compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3431861A1 (de) * 1984-08-30 1986-03-13 Troponwerke GmbH & Co KG, 5000 Köln Pellet-zubereitung
ATE71293T1 (de) * 1986-09-18 1992-01-15 London Pharmacy Innovation Arzneiformulierung.

Also Published As

Publication number Publication date
EP0526862B1 (en) 1996-02-14
IT1251153B (it) 1995-05-04
ATE134134T1 (de) 1996-02-15
DE69208299T2 (de) 1996-07-18
DE69208299D1 (de) 1996-03-28
ITMI912212A1 (it) 1993-02-07
ITMI912212A0 (it) 1991-08-06
EP0526862A1 (en) 1993-02-10

Similar Documents

Publication Publication Date Title
ES2086029T3 (es) Composiciones farmaceuticas solidas para la administracion oral con permanencia gastrica prolongada.
DE69532415D1 (de) Schmelzextrudierte oral verabreichbare opioidformulierungen
SE9301171D0 (sv) Pharmaceutical composition containing lipophilic drugs
NO20100302L (no) Sammensetninger som inneholder organiske forbindelser
ES2152966T3 (es) Formas de dosificado farmaceuticas de desleido rapido y procedimiento para su preparacion.
DK0841903T3 (da) Orale farmaceutiske præparater indeholdende antimikrobielt virksomme aktivstoffer og sustained release pantoprazol
RS50768B (sr) Režim doziranja i farmaceutska formulacija za urgentnu zaštitu
ATA186692A (de) Pharmazeutische zusammensetzung
PT770384E (pt) Composicoes farmaceuticas solidas anidras para utilizacao vaginal
ATE318575T1 (de) Orale zubereitung chlorhexidin und maltitol oder erythritol oder deren mischung enthaltend
DE3783923T3 (de) Einen Wirkstoff und ein in Wasser quellendes Polymer enthaltendes Arzneimittel.
DK1109538T3 (da) Antiinflammatoriske farmaceutiske formuleringer
DE3871159D1 (de) Pharmazeutische und tieraerztliche zusammensetzungen.
ATE175870T1 (de) Pharmazeutische zubereitung zur rektalen verabreichung von pharmakologisch wirksamen verbindungen
AR026756A1 (es) Nuevas combinaciones terapeuticas (s)-2-bencilamino-metil)-2,3,8,9-tetrahidro-7h-1,4-dioxino[2,3-e]indol-8-ona y neuroleticos para el tratamiento oprevencion de desordenes psicoticos
CY1108440T1 (el) Σκευασμα δοσολογιας υδροφιλης/λιποφιλης πολυμερους μητρας περιεχουσας ροπινιρολης
BR9805026A (pt) Compostos contdndo tetrahidrolipstatina

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 526862

Country of ref document: ES